Search

Displaying results 4071 - 4080 of 7283 in total
  1. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  2. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … It is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  3. Drug

    Tizaterkib

    go.drugbank.com/drugs/DB21296
    Investigational

    Tizaterkib has a monoisotopic molecular weight of 494.2 Da. … Tizaterkib is a small molecule drug. The usage of the INN stem '-terkib' in the name indicates that Tizaterkib is a extracellular signal-regulated kinase (ERK) inhibitor.

  4. Drug

    Mizacorat

    go.drugbank.com/drugs/DB21458
    Investigational

    Mizacorat has a monoisotopic molecular weight of 494.21 Da. … Mizacorat is a small molecule drug. The usage of the INN stem '-corat' in the name indicates that Mizacorat is a glucocorticoid receptor agonist.

  5. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK

  6. Drug

    Desloratadine

    go.drugbank.com/drugs/DB00967
    ApprovedInvestigational

    Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. … It is the active descarboethoxy metabolite of loratidine (a second generation histamine).

    Mixtures: Clarinex-D 12 Hour, Clarinex-D 24 HourProducts: GLOBISTAMIN D, GLOBISTAMIN D JARABE
  7. Drug

    Eprodisate

    go.drugbank.com/drugs/DB06405
    Investigational

    Eprodisate slows the decline of renal function in AA amyloidosis.

  8. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47526] It is considered one of the most likely agents to be used in a biological attack. … [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.

    Categories: Complex Mixtures
  9. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. … [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.

  10. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood … Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect.

    Categories: Venombin A, Complex Mixtures